QualityStocksNewsBreaks – Endonovo Therapeutics Inc. (ENDV) Posts Q2 2019 Financial Results

Endonovo Therapeutics (OTCQB: ENDV) on Tuesday posted the company’s financial and operating results for the second quarter. The company reported revenues for the three months ended June 30, 2019 of $62,729, a sharp increase compared to $12,854 for the same period last year. Gross profits for the second quarter were $33,156, as compared to $12,304 for the same period last year. Endonovo also provided an update on the PEMF assets it acquired from Rio Grande Neurosciences for $4.5 million in December 2017. “I am pleased to announce we have executed the business plan and strategy we implemented after acquiring the PEMF assets and technology in December 2017, and I am additionally excited to announce the results we attained throughout the first six months of this year. Our sales network in 2018 included two distributors and several independent sales representatives throughout the United States, which began our sales and marketing efforts for SofPulse(R), ultimately leading to our revenues. Throughout 2019 we expanded our team of independent sales representatives, began our marketing launch into the U.S. hospitals and we are focusing on expanding nationally,” Endonovo Therapeutics CEO Alan Collier stated in the news release.

To view the full press release, visit http://ibn.fm/FroSI

About Endonovo Therapeutics Inc.

Endonovo Therapeutics is a commercial-stage developer of noninvasive wearable Electroceutical Therapeutic devices. The company’s current portfolio of commercial and clinical-stage wearable Electroceutical Therapeutic devices addresses wound healing, pain, postsurgical pain and edema, cardiovascular disease, chronic kidney disease and central nervous system (“CNS”) disorders, including traumatic brain injury (“TBI”), acute concussions, postconcussion syndrome and multiple sclerosis. The company’s noninvasive Electroceutical Therapeutic device, SofPulse(R), using pulsed short-wave radiofrequency at 27.12 MHz, has been FDA cleared and CE marked for the palliative treatment of soft-tissue injuries and postoperative pain and edema, and has CMS national coverage for the treatment of chronic wounds. The company’s current portfolio of preclinical-stage Electroceuticals Therapeutic devices address chronic kidney disease, liver disease nonalcoholic steatohepatitis (“NASH”), cardiovascular and peripheral artery disease (“PAD”), and ischemic stroke. The company’s noninvasive, wearable Electroceutical Therapeutic devices work by restoring key electrochemical processes that initiate anti-inflammatory and growth-factor cascades necessary for healing to occur. For more information, visit the company’s website at www.Endonovo.com.

NOTE TO INVESTORS: The latest news and updates relating to ENDV are available in the company’s newsroom at http://ibn.fm/ENDV

About QualityStocksNewsBreaks

QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php